IDEXX Laboratories (NASDAQ:IDXX) EVP Sells $1,115,574.06 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP Nimrata Hunt sold 1,758 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Nimrata Hunt also recently made the following trade(s):

• On Thursday, February 26th, Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22.

IDEXX Laboratories Stock Down 1.7%

Shares of NASDAQ IDXX opened at $608.41 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The business has a fifty day moving average of $666.94 and a two-hundred day moving average of $668.42. The stock has a market cap of $48.44 billion, a PE ratio of 46.55, a PEG ratio of 3.70 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IDXX. EverSource Wealth Advisors LLC lifted its position in shares of IDEXX Laboratories by 2.5% during the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after purchasing an additional 15 shares in the last quarter. STF Management LP increased its holdings in shares of IDEXX Laboratories by 1.3% in the second quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after purchasing an additional 16 shares in the last quarter. Clearstead Trust LLC increased its holdings in shares of IDEXX Laboratories by 1.1% in the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after purchasing an additional 16 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in IDEXX Laboratories by 4.4% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after purchasing an additional 16 shares during the last quarter. Finally, Harbour Investments Inc. raised its position in IDEXX Laboratories by 13.3% in the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after purchasing an additional 16 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of several research analyst reports. UBS Group decreased their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 3rd. Piper Sandler cut their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Barclays reduced their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Finally, BTIG Research cut their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.